Carboplatin-induced regression of an optic pathway tumor in a child with neurofibromatosis.
Optic pathway tumors are common in children with neurofibromatosis-1 (NF-1). The optimal management of these tumors is unknown, particularly when the optic chiasm and other brain structures are involved. We report the dramatic response to carboplatin in a 10-year-old girl with NF-1 and a progressive optic pathway tumor. Tumor shrinkage was accompanied by striking improvement in visual fields, return of color discrimination, and marked improvement in visual acuity. No significant toxicity was observed. One year following completion of chemotherapy the glioma remains as small or smaller than it was at the conclusion of therapy, and there has been no deterioration of vision. Carboplatin is a promising agent for the treatment of optic pathway tumors in children with NF-1.
Charrow
J
J
Division of Genetics, Children's Memorial Hospital, Chicago, Illinois 60614.
Listernick
R
R
Greenwald
M J
MJ
Das
L
L
Radkowski
M A
MA
D016190:Carboplatin / Q000627:therapeutic use*; D002648:Child; D003118:Color Perception / Q000187:drug effects; D003390:Cranial Nerve Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009378:Neoplasms, Multiple Primary / Q000473:pathology*; D009456:Neurofibromatosis 1 / Q000473:pathology*; D009901:Optic Nerve Diseases / Q000188:drug therapy* / Q000473:pathology; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
D016190:Carboplatin